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Abstract
To study the interaction between HIV and other carcinogenic infections in conjuncti-
val squamous cell carcinoma (SCC), we evaluated the presence of a broad spectrum
of human viruses in conjunctiva specimens. Beta Human papillomavirus (HPV;
n = 46), gamma HPV (n = 52), polyomaviruses (n = 12) and herpes viruses (n = 3) was
determined in DNA extracted from 67 neoplastic and 55 non-neoplastic conjunctival
tissues of HIV-positive and HIV negative subjects by Luminex-based assays. Next-
generation sequencing (NGS) was also used to further characterize the presence of
cutaneous HPVs. Detection of beta-2 HPV infections was associated with the risk of
neoplasia (adjusted odds ratio [aOR] 3.0; 95% confidence interval [CI] 1.3-6.8),
regardless of HIV status (HIV positive, aOR 2.6, 95% CI 0.9-7.7; HIV negative, aOR
3.5, 95% CI 0.9-14.4). EBV was strongly associated with the risk of neoplasia (aOR
12.0, 95% CI 4.3-33.5; P < .01) mainly in HIV individuals (HIV positive, aOR 57.5;
95% CI: 10.1-327.1; HIV negative aOR 2.6; 95% CI: 0.2-34.7). NGS allowed to iden-
tify 13 putative novel HPVs in cases and controls. Our findings suggest a role of beta
HPV types and EBV, in conjunctival SCC. However, additional studies of viral expres-
sion in tumor tissue are required to confirm the causal association.
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1 | INTRODUCTION
Squamous cell carcinoma (SCC) of the conjunctiva is a malignant dis-
ease of the eyes grouped in ocular surface squamous neoplasia
(OSSN).1 OSSN includes different types of lesion with various degrees
of dysplasia, carcinoma in situ and invasive squamous cell carcinoma
of cornea and conjunctiva.2 Incidence of conjunctival SCC has a large
geographic variability, with high incidence rates occurring in Africa
(about 1.3 per 100 000 person-years), while it is considered rare in
other regions of the world (about 0.1 per 100 000 person-years).3,4
Ultraviolet (UV) radiation represents the most important etiological
factor of conjunctival SCC.5 The impairment of the immune system
also appears to contribute to conjunctival SCC development.6 Indeed,
HIV-positive individuals have nearly 10-fold increased risk of develop-
ment of conjunctival SCC in comparison to HIV-negative population.7
Accordingly, this pathological condition has greatly increased in
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several African countries in the last decades, coinciding with the
spread of HIV infection.8,9 In addition, an increased incidence rate of
conjunctival SCC has been observed in Australian subtropical area in
immune-compromised individuals after renal transplantation.10 The
apparent link of the immune suppression and development of con-
junctival SCC strongly suggests the involvement of infectious agents
in the etiology of this type of cancer. Several studies showed that
cutaneous beta-HPV types were more present in conjunctival SCC
rather than other nonmalignant eye conditions.11-13 A few studies
also suggested the involvement of mucosal high-risk alpha HPV types
in the conjunctival SCC development, however other studies did not
support this association.14-18 Finally, some studies investigated the
role of additional human viruses, such as Epstein-Barr virus (EBV),
Kaposi's sarcoma-associated herpesvirus (KSHV), Herpes Simplex
Virus (HSV) and Cytomegalovirus (CMV) in both OSSN and UV-
related noncancerous eye conditions, as pterygium.6,19,20 Thus, the
etiological role of an infectious agent in conjunctival SCC remains a
matter of debate and deserves more investigation.
In our study, we have evaluated the presence of a broad spectrum
of cutaneous human papillomaviruses, herpesviruses and poly-
omaviruses using highly sensitive Luminex-based assays in conjuncti-
val samples. The study included HIV-positive and HIV-negative cancer
free-subjects as well as those with precancerous and cancerous
lesions recruited in a previous case-control study.21 In addition, the
Luminex assay was complemented by the use of a next-generation
sequencing (NGS)-based strategy to further evaluate the possible
presence of additional novel or already characterized cutaneous HPV
types.
2 | MATERIALS AND METHODS
2.1 | Study population and biological specimens
We have analyzed total DNA extracted from conjunctival tissues
(n = 67 cases) including conjunctival intraepithelial neoplasia (CIN
1 = 15; CIN 2 = 15, CIN3 = 15), and conjunctiva squamous cell carci-
noma SCC (n = 22) as described in a previously published study.21
Conjunctiva non-neoplastic biopsies (n = 55 controls) obtained from
the same study were also analyzed.21 Briefly, subjects with conjunc-
tiva neoplasia were enrolled in seven countrywide eye clinics in
Southern Uganda between January 1997 and March 1999. In the
same clinics, tissue specimens were collected also for control subjects
that were randomly enrolled among patients presenting benign lesion
(eg, pterygium) or eye injuries. Peripheral whole blood samples were
obtained from all case patients and control subjects at surgical
removal of conjunctival lesions and serum tested for anti-HIV1/2 anti-
bodies by enzyme-linked immunosorbent assay (ELISA). Positive sam-
ples were further tested by immunoblotting. All enrolled subjects did
not receive antiretroviral treatments, since they were adopted in
Uganda in 2004 after the collection of the specimens used in our
study. No information on the CD4 lymphocyte count was available.
However, the majority of HIV-positive patients and controls were
classified as WHO clinical Stage 1 and only three cases classified as
WHO clinical Stage 2.
Total DNA extracted from specimens of cases (n = 86) and controls
(n = 63) were previously analyzed for the presence of alpha and beta
HPVs.21 Part of these samples was further analyzed for HHV8 infection
(72 cases and 60 controls)20 as well as for TERT promoter mutations (67
cases and 55 controls).34 In the present study, we have analyzed the sam-
ples that remained available after the completion of the previous studies.
Total nucleic acids were extracted in Naples as previously described21 and
were analyzed by Luminex and NGS at IARC (Lyon, France).
2.2 | Detection of viral DNA by Luminex assay and
statistical analysis
The prevalence of several infectious agents was determined by using
type-specific multiplex genotyping (TS-MPG) assays, which combine
multiplex polymerase chain reaction (PCR) and bead-based Luminex
technology (Luminex Corp., Austin, Texas), as described previously.22-
26 Multiplex PCR amplifications using type-specific primers were used
for the detection of 46 genus beta-HPV types (HPV5, HPV8, HPV9,
HPV12, HPV14, HPV15, HPV17, HPV19, HPV20, HPV21, HPV22,
HPV23, HPV24, HPV25, HPV36, HPV37, HPV38, HPV47, HPV49,
HPV75, HPV76, HPV80, HPV92, HPV93, HPV96, HPV98, HPV99,
HPV100, HPV104, HPV105, HPV107, HPV110, HPV111, HPV113,
HPV115, HPV118, HPV120, HPV122, HPV124, HPV143, HPV145,
HPV150, HPV151, HPV152, HPV159 and HPV174), 52 genus
gamma-HPVs (HPV4, HPV48, HPV50, HPV60, HPV65, HPV88,
HPV95, HPV101, HPV103, HPV108, HPV109, HPV112, HPV116,
HPV119, HPV121, HPV123, HPV126, HPV127, HPV128, HPV129,
HPV130, HPV131, HPV132, HPV133, HPV134, HPV148, HPV149,
HPV156, HPV161, HPV162, HPV163, HPV164, HPV165, HPV166,
HPV167, HPV168, HPV169, HPV170, HPV171, HPV172, HPV173,
HPV175, HPV178, HPV179, HPV180, HPV184, HPV197, HPV199,
HPV200, HPV201, HPV202 and SD2), 12 polyomaviruses (BKV, JCV,
KIV, WUV, MCPyV, HPyV6, HPyV7, TSV, HPyV9, HPyV10, HPyV12
What's new?
Risk of conjunctival squamous cell carcinoma (SCC) is
strongly associated with ultraviolet radiation exposure and
immune suppression. In Africa, SCC incidence has also been
affected by the spread of HIV and may be impacted by other
viral infections. Here, analyses of a large number of viruses
in conjunctival non-malignant and malignant tissues from
patients in Southern Uganda reveal associations between
conjunctival SCC and cutaneous beta human papillomavirus
(HPV) and Epstein-Barr virus (EBV) infection. Beta-2 HPV
infection was linked to neoplasia risk regardless of HIV sta-
tus, whereas EBV was associated with neoplasia primarily in
HIV-infected individuals.
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and LIPyV) and three herpesviruses (CMV, EBV1 and EBV2). Two
primers for the PCR amplification of beta-globin gene were also used
to assess the quality of the extracted DNA. After PCR amplification,
10 μL of each reaction was analyzed by multiplex using a Luminex-
based assay as described in detail previously.25,27
Prevalence of infectious agents is given as a percentage and
corresponding 95% confidence intervals (95% CI) were calculated
according to the binomial distribution. Odds ratios (ORs) and 95% CIs
were calculated using unconditional logistic regression models and
were adjusted for age and sex.
2.3 | Next-generation sequencing procedures
Extracted DNA was amplified using two different sets of primers (FAP59
\FAP64 and FAPM1 primer mix) as previously described.28,29 Both FAP
and FAPM1 primer sets target a region of the L1 ORF yielding an amplicon
of about 480 bp. PCR amplicons were visualized by electrophoresis on a
1.5% agarose gel and purified using QIAquick gel extraction purification kit
according to the manufacturer's instructions (QIAGEN, Hilden, Germany).
Purified PCR amplicons of the expected size were divided into four differ-
ent pools using the same volume of each purified amplicons, according to
the PCR protocol and conjunctiva specimens as reported in Table 1.
Before library preparation, one additional purification step was per-
formed in each pool to remove any residual contaminants using the
Agencourt AMPure XP PCR purification kit with a beads ratio of 1.8 X
(Beckman Coulter) according to the manufacturer's instructions. The
amplicon-based libraries were prepared using the Nextera DNA Flex
Library preparation kit (Illumina, San Diego, California). Illumina MiSeq
dual-indexed adapters (Illumina, San Diego, California) were added to
each of the PCR pools. The library sizes were checked using the
ScreenTape System (Agilent) using high sensitivity assay. NGS analysis
was performed on 4 nM of DNA pooled library using the Illumina bench-
top MiSeq sequencer (2 × 150 paired-end reads with the Illumina MiSeq
kit v3). To enrich the diversity of the libraries, 10% of PhiX (Illumina, San
Diego, California) was added to the NGS reaction.
2.4 | Bioinformatic analysis
All the bioinformatic analyses were performed using PVAmpliconFinder
(https://github.com/IARCbioinfo/PVAmpliconFinder), and the main steps
are described as follow. The row data were first preprocessed for quality
control and filtering. Several steps of data complexity reduction were
applied, and DNA sequences were subsequently identified based on sim-
ilarity when compared against available PVs sequences in the NCBI data-
base. DNA sequences were assigned as a known HPV type when it
showed a high identity of more than ≥90% with L1 ORF of the closest
HPV type. A putative novel HPV sequence was assigned as a putative
new HPV type when reported a low identity of less than <90% with L1
ORF of the closest PV. De-novo reconstruction of the fully amplified
region covered by several primers systems was performed. Finally, the
reconstructed sequences were taxonomically classified by both align-
ment-based and homology-based methodologies. All the results in our
study are based on the homology-based classification using the evolu-
tionary placement algorithm (EPA) in RAxML (Randomized Axelerated
Maximum Likelihood).29,30 Only the longest sequence was considered
for the RAxML-EPA classification when several singlets or contigs were
available.
3 | RESULTS
3.1 | Detection of viral DNA by Luminex assay
We analyzed the neoplasia cases (n = 67) included different grades
of conjunctival intraepithelial neoplasia (CIN 1, n = 15; CIN 2,
n = 15, CIN3, n = 15), and conjunctiva squamous cell carcinoma
cSCC (n = 22), and the cancer-free controls (n = 55) for the pres-
ence of cutaneous beta and gamma HPV types, polyomaviruses and
herpesviruses by Luminex-based assays. The median age of the
study population was 32 years (IQR, 27-40), of them 49.2% (n = 60)
were female while 50.8% (n = 62) were male (Table 2). The propor-
tion of neoplastic lesions was significantly higher in females
(59.7%) compared to males (40.3%; P = .01; Table 2). In the neopla-
sia and control group, 64.2% (n = 43/67) and 54.5% (n = 30/55),
respectively, were positive for HIV. The samples were all positive
for beta-globin gene thus being valid for the analysis. Beta HPV
types were found in 45.4% (n = 25/55) and 61.2% (n = 41/67) of
controls and neoplasia group, respectively, but the difference was
not statistically significant. However, the stratification of the beta
HPV types into the different species revealed a significantly higher
beta-2 HPV prevalence in cases (P < .01; Table 2 and Figure 1).
Such association remained significant also after adjustment for age,
and sex (aOR 3.0; 95% CI: 1.3-6.8; Table 3). When stratified by HIV
status, no clear difference in beta 2-positivity between HIV-posi-
tive (aOR 2.6; 95% CI: 0.9-7.7) and HIV-negative subjects (aOR 3.5;
95% CI: 0.9-14.4) was found (Table 4). On the contrary, there was
no statistically significant association between neoplasia and beta-
1 HPV types (P = .25; Tables 2 and 3 and Figure 1). The most preva-
lent HPV types in beta-1 species were HPV5 (n = 15) and 24
(n = 8), in beta-2 species were HPV38 (n = 21) and HPV100 (n = 8),
and in beta-3 species was HPV75 (n = 12). However, there was a
significant difference between cases and controls only for HPV5
(aOR 9.1; 95% CI: 1.1-75.0; P = .04; data not shown).
TABLE 1 Description of the NGS pools stratified according to
conjunctiva samples and PCR protocol
NGS pool PCR primers Sample group Total number
1 FAP59-FAP64 Conjunctiva casesa 33
2 FAPM1 Conjunctiva casesa 17
3 FAP59-FAP64 Conjunctiva controls 24
4 FAPM1 Conjunctiva controls 43
Note: Each pool is constituted of PCR products that gave an amplicon of
about 500 bp with the indicated primers.
aCases group includes conjunctiva papilloma (n = 1).
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The remaining HPV types that belong to beta species 3 to 5 were
less abundantly detected (beta-3) (Table 2) or absent (beta 4-5) in
both groups.
Gamma HPVs were detected in 13.9% (n = 17/122). Of
these 10.9% (n = 6/55) were in controls and 16.4% (n = 11/67) in
cases, respectively. Regarding gamma-HPV types, no significant differ-
ences were found between cases and controls (P = 0.48; Table 2).
Regarding the polyomaviruses (HPyVs), the most prevalent was
MCPyV (35.3%) as shown in Table 2. However, no significant differ-
ence in prevalence between cases and control was found (P = .13).
Some of the remaining PyVs tested were rarely detected or absent
(data not shown).
Regarding the tested herpes viruses, CMV was detected in 5.4%
(n = 3) of controls and in 8.9% of cases (n = 6), while EBV1 and 2 were
TABLE 2 Characteristics of the study population
All (122) n (%) Controlsa (55) n (%) Cases (67) n (%) Pb
Age (median [IQR]) 32 (27-40) 32 (26-40) 32 (27-40)
<30 41 (33.6) 17 (30.9) 24 (35.8)
30 to 39 47 (38.5) 21 (38.2) 26 (38.8)
40+ 34 (27.9) 17 (30.9) 17 (25.4) .47
Sex
Female 60 (49.2) 20 (36.4) 40 (59.7)
Male 62 (50.8) 35 (63.6) 27 (40.3) .01
HIV status
Negative 49 (40.2) 25 (45.5) 24 (35.8)
Positive 73 (59.8) 30 (54.5) 43 (64.2) .35
EBV1 and EBV2
Negative 75 (61.5) 49 (89.1) 26 (38.8)
Positive 47 (38.5) 6 (10.9) 41 (61.2) <.01
EBV1
Negative 87 (71.3) 49 (89.1) 38 (56.7)
Positive 35 (28.7) 6 (10.9) 29 (43.3) <.01
EBV2
Negative 93 (76.2) 52 (94.5) 41 (61.2)
Positive 29 (23.8) 3 (5.5) 26 (38.8) <.01
MCPyV
Negative 79 (64.8) 40 (72.7) 39 (58.2)
Positive 43 (35.3) 15 (27.3) 28 (41.8) .13
β-HPV [46]
Negative 56 (45.9) 30 (54.5) 26 (38.8)
Positive 66 (54.1) 25 (45.5) 41 (61.2) .10
β1-HPV [19]
Negative 82 (67.2) 40 (72.7) 42 (62.7)
Positive 40 (32.8) 15 (27.3) 25 (37.3) .25
β2-HPV [20]
Negative 77 (63.1) 42 (76.4) 35 (52.2)
Positive 45 (36.9) 13 (23.6) 32 (47.8) <.01
β3-HPV [4]
Negative 108 (88.5) 49 (89.1) 59 (88.1)
Positive 14 (11.5) 6 (10.9) 8 (11.9) .86
γ-HPV [52]
Negative 105 (86.1) 49 (89.1) 56 (83.6)
Positive 17 (13.9) 6 (10.9) 11 (16.4) .48
aControls includes conjunctiva papilloma, pinguecula and inflammation (n = 4).
bPearson's Chi-square test.
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abundantly detected in both groups (38.5%) as shown in Table 2 and
Figure 1. However, EBV prevalence was much higher in the neoplasia
group than controls, 61.2% vs 10.9%, respectively (P = <.01) (Table 2
and Figure 1). EBV remained significantly associated also after adjust-
ment for age, and sex (aOR 12.0; 95% CI: 4.3-33.5; Table 3). Preva-
lence of EBV1 and EBV2 was significantly higher in the neoplastic
group (P < .01) than the controls (Table 2). Stratified by HIV status,
the EBV-positivity was strongly associated with cases (aOR 57.5; 95%
CI: 10.1-327.1) in HIV-positive individuals. On the contrary, the EBV-
positivity was not associated with cases in HIV-negative individuals
(aOR 2.6; 95% CI: 0.2-34.7; P = .47; Table 4).
Of note, by severity of histological lesion, prevalence of EBV in
HIV-positive individuals was 81.8%, 100% and 100% for CIN1, CIN2
and CIN3, respectively and 85.7% in SCC, being significantly higher
than the control (P for trend < .01; Table 5).
3.2 | HPVs broad-spectrum analysis by NGS
To have a broader view on the distribution of HPV types in cases and
controls we have performed NGS analysis. A total of 2 415 171
paired-end raw reads was obtained for the NGS analysis. After quality
F IGURE 1 Prevalence of indicated viruses and corresponding 95% confidence intervals (CI) in controls and neoplasia groups
TABLE 3 Odds ratio for positivity of EBV1&EBV2, β1-HPV and β2-HPV and corresponding 95% confidence Interval
Controlsa (55) n (%) Cases (67) n (%) OR [95% CI] P aORa [95% CI] P
EBV1 & EBV2
Negative 49 (89.1) 26 (38.8) Ref Ref
Positive 6 (10.9) 41 (61.2) 12.6 [4.8-34.3] <.01 12.0 [4.3-33.5] <.01
β1-HPV
Negative 40 (72.7) 42 (62.7) Ref Ref
Positive 15 (27.3) 25 (37.3) 1.6 [0.7-3.4] .24 1.3 [0.6-2.9] .54
β2-HPV
Negative 42 (76.4) 35 (52.2) Ref Ref
Positive 13 (23.6) 32 (47.8) 3.0 [1.3-6.5] <.01 3.0 [1.3-6.8] .01
aAdjusted on age and sex.
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trimming, de-replication, and chimeric PCR sequence removal,
2 548 514 reads were considered for further analysis. Approximately
58.7% (1 498 086 reads) were related to known HPVs and 0.03%
(785 reads) to novel putative PVs. According to the similarity with
available PV sequences in the NCBI database, a total of 207 known
and 13 putative new HPV sequences were detected in our study
(Tables S1 and S2).
Among the known HPV sequences the alpha-related reads (gen-
erated by both FAP and FAPM1 PCR protocols) in pools 1-2 (cases) vs
3-4 (controls) was of 502 602 (19%) and 75 reads (0.002%) respec-
tively. The majority of the reads in cases pools were referred to
HPV11 (200 868 and 298 441 reads obtained with FAP and FAPM1
primers, respectively).
A total of 685 432 reads (26.9%) were assigned to beta-HPV
types; 366 593 (14.4%) reads were detected in cases while the control
group generated 318 839 (12.5%) sequences. In detail, the number of
reads related to beta-1 species was 266 367 in cases vs 249 437 in
controls, while 64 338 reads in cases and 69 227 reads in controls
were related to beta-2 species. The number of reads from beta-3 spe-
cies was higher in cases (25 319 reads) than in controls (156 reads).
Beta-5 species (166 reads) reads were exclusively found in cases. As
previously suggested by the Luminex analysis, no sequences from
beta-4 species were found in both groups.
Specifically, the number of reads of the following HPV types
HPV5 (β-1), 8 (β-1), HPV19 (β-1), HPV24 (β-1), HPV38 (β-2), HPV49
(β-3) and HPV75 (β-3) were exclusively detected or predominant in
cases vs controls (Table S1). While the number of reads of other HPV
types, for example, HPV12 (β-1), HPV14 (β-1), HPV23 (β-2) and
HPV104 (β-2), had the opposite trend (Table S1). A small number of
reads (10 403 reads in cases and 19 reads in controls) corresponded
to beta unreferenced HPVs.
A total of 161 698 (6.3%) and 64 240 (2.5%) gamma-HPV types
related sequences was detected in cases and controls, respectively,
spreading into different gamma species or unreferenced-HPV gamma
types (Table S1).
Finally, 785 reads (0.03%) allowed the identification of 13
putative novel PVs, as their sequences showed less than 90% simi-
larity to L1 ORF of any known PVs. According to RaxML-EPA clas-
sification, the putative novel sequences were closely related to
beta-1, beta-2 and gamma-1, 11, 15 and other unreferenced HPVs.
TABLE 4 Odds ratio for positivity of EBV1&EBV2 and β2-HPV and corresponding 95% confidence interval by HIV status
Controlsa (55) n (%) Cases (67) n (%) OR [95% CI] P aORb [95% CI] P
HIV positive
EBV1&EBV2 negative 25 (83.3) 4 (9.3) Ref Ref
EBV1&EBV2 positive 5 (16.7) 39 (90.7) 48.8 [11.9-199.2] <.01 57.5 [10.1-327.1] <.01
HIV negative
EBV1&2 negative 24 (96.0) 22 (91.7) Ref Ref
EBV1&2 positive 1 (4.0) 2 (8.3) 2.2 [0.2-25.8] .54 2.6 [0.2-34.7] .47
HIV positive
β2-HPV negative 21 (70.0) 20 (46.5) Ref Ref
β2-HPV positive 9 (30.0) 23 (53.5) 2.7 [1.0-7.2] <.05 2.6 [0.9-7.7] .09
HIV negative
β2-HPV negative 21 (84.0) 15 (62.5) Ref Ref
β2-HPV positive 4 (16.0) 9 (37.5) 3.2 [0.8-12.2] .10 3.5 [0.9-14.4] .08
a Controls includes conjunctiva papilloma, pinguecula and inflammation (n=4). .
bAdjusted on age and sex.
TABLE 5 EBV positivity in controls and preneoplastic/neoplastic conjunctival lesions, by HIV status
Controls n (%) CIN 1 n (%) CIN 2 n (%) CIN 3 n (%) SCC n (%) P for trend
All participants
EBV-negative 49 (89.1) 6 (40.0) 5 (33.3) 6 (40.0) 9 (40.9)
EBV-positive 6 (10.9) 9 (60.0) 10 (66.7) 9 (60.0) 13 (59.1) <.01
HIV negative
EBV-negative 24 (96.0) 4 (100) 5 (100) 6 (85.7) 7 (87.5)
EBV-positive 1 (4.0) 0 (0.0) 0 (0.0) 1 (14.3) 1 (12.5) .28
HIV positive
EBV-negative 25 (83.3) 2 (18.2) 0 (0.0) 0 (0.0) 2 (14.3)
EBV-positive 5 (16.7) 9 (81.8) 10 (100) 8 (100) 12 (85.7) <.01
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The majority of the putative novel PVs (n = 11) were found in cases
(Table S2).
4 | DISCUSSION
The association between UV with conjunctival SCC is well
established.30,31 In addition, impairment of the immune system by
HIV, or in solid organ transplant recipients (SOTR), appears to be a
marked risk factor for conjunctival SCC.7 The fact that immune-sys-
tem impairment increases the susceptibility to conjunctival SCC,
strongly suggests the involvement of infectious agents in this disease.
Several studies present evidence for the contribution of HPV to con-
junctival SCC,6,19,20 although this association remains controversial.
Our study showed that beta-2 HPV infections was associated with
the risk of neoplasia (aOR 3.0; 95% CI 1.3-6.8), as previously reported
for cutaneous SCC.32 Thus, the proposed scenario in conjunctival SCC
appears to share similarities with the one proposed for the skin carci-
nogenesis, where UV radiation is the leading risk factor together with
immunosuppression.33 This similarity is further underlined by the
mutation profile detected in both SCCs.34 Solid organ transplant
recipients (SOTR) have about 100-fold risk of cutaneous SCC in com-
parison to the healthy individuals.35 Interestingly, a previous study
reported that the incidence of conjunctival OSSN, including conjuncti-
val SCC, was 20-fold increase in kidney transplantation subjects living
in the Australian subtropical area.10 Importantly, these OTRs had also
history of cutaneous SCC, suggesting that both type of cancers share
the same etiological factors.10
Our Luminex data showed that HPV5 and 24 from beta-1 species
and HPV38 and HPV100 from beta-2 species were the most preva-
lent types in cases and controls. Among them, only HPV5 was the
only significantly associated with cases (aOR 9.1; 95% CI: 1.1-75.0;
P = .04). HPV types 5, 24, 38 and 100 were previously detected in
other case-control studies.11-13,21 IARC has classified beta-1 species
HPV5 and HPV8 as “possibly carcinogenic” agents (Group 2B) in skin
lesions in Epidermodysplasia verruciformis patients.36 Beta types such
as HPV5, HPV12, HPV24 and HPV38 were also frequently reported
in multiple anatomic sites.37 Interestingly, beta-3 species HPV75 was
frequently found in our study (overall prevalence 9.8%), while in other
studies, this type was rarely found compared to the other beta-3 HPV
types (eg, HPV49 and HPV76) at different anatomical sites.37,38
Interestingly, our results are also in line with other studies on
cutaneous SCC. Using different viral markers, these studies reported a
more significant association of beta-2 HPV types with risk of cutane-
ous SCC development in comparison to the other beta species.32,39,40
Our complementing strategy using NGS, revealed the presence of
reads assigned to alpha-species in ocular tissues, confirming the previ-
ous findings from Tornesello et al.21 We also observed a correlation
between the Luminex-based prevalence study and the NGS data.
Most of the HPV types were detected by both methodologies. In
addition, by using two PCR protocols combined with NGS a total of
13 putative novel HPVs were identified. According to RaxML-EPA
classification, the putative novel sequences were phylogenetically
related to HPV9, HPV20, HPV205, HPV213, HPV173, HPV169,
HPV179 and unreferenced γ-HPVs (HPV-mw11C39 and HPV-
mSK123). Eleven of them were found exclusively in cases. However,
the NGS findings have the limitation due to the pool-based strategy,
which does not allow the determination of prevalence of specific
HPVs in case and controls.
Our Luminex results also show that EBV is significantly associated
with cases (aOR 12.0; 95% CI: 4.3-33.5). Furthermore, the EBV-posi-
tivity was strongly associated with cases in HIV-positive individuals
(aOR 57.5; 95% CI: 10.1-327.1), while the same result was not seen in
HIV-negative (aOR 2.6 95% CI: 0.2-34.7; P = .47). Our data support a
role of EBV in the development of conjunctival SCC, as in other
human cancers, such as nasopharyngeal SCC.7 Moreover, the compa-
rable trend of EBV prevalence in conjunctiva SCC and in conjunctival
lesions (CIN1-CIN3) suggests that the virus is involved in early stage
of neoplasia development all the way to tumor development. This
suggests that EBV may be the, as yet undiscovered, carcinogenic
agent that is expected to be working in synergy with HIV-related
immunosuppression to cause conjunctiva SCC. Indeed, of all the can-
cer types established to be caused by HIV, conjunctiva SCC remains
the only one for which there is not an established underlying infec-
tious cause.7
However, our results cannot conclusively prove that EBV plays
a direct role in the development of conjunctival SCC. It is also pos-
sible that EBV positivity in cancer tissue as well as in premalignant
lesions of HIV-positive individuals is due to the presence of infil-
trating viral-infected B lymphocytes.41 To evaluate both possibili-
ties additional analyses of conjunctiva SCC tissues are required,
aiming to precisely determine the presence of different EBV
markers (eg, EBNA 1 immunohistochemistry staining) in epithelial
and/or B cells.
In conclusion, our findings reinforce the hypothesis that conjunc-
tival SCC development is linked to viral infections. Whether EBV is
present in cancer cells or in B-cell recruited at cancer site remain to
be demonstrated. Importantly, it is essential to corroborate these data
conducting similar studies in other geographical area with high con-
junctival SCC incidence.
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